OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. [electronic resource]
Producer: 20080805Description: 5206-15 p. digitalISSN:- 1538-7445
- Animals
- Antibodies -- therapeutic use
- Antibodies, Monoclonal -- pharmacology
- Antineoplastic Agents -- pharmacology
- CD8 Antigens -- metabolism
- Carcinoma -- drug therapy
- Chemotaxis, Leukocyte -- drug effects
- Colorectal Neoplasms -- drug therapy
- Drug Evaluation, Preclinical
- Immune Tolerance -- drug effects
- Macrophages -- drug effects
- Mammary Neoplasms, Animal -- drug therapy
- Membrane Glycoproteins -- agonists
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Mice, Knockout
- Neoplasms -- drug therapy
- OX40 Ligand
- T-Lymphocytes, Regulatory -- drug effects
- Tumor Cells, Cultured
- Tumor Escape -- drug effects
- Tumor Necrosis Factors -- agonists
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.